- Home
- ROIV vs HALO Comparison
ROIV vs HALO Comparison
Compare ROIV & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- HALO
- Stock Information
- Founded
- ROIV 2014
- HALO 1998
- Country
- ROIV United Kingdom
- HALO United States
- Employees
- ROIV N/A
- HALO N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ROIV Health Care
- HALO Health Care
- Exchange
- ROIV Nasdaq
- HALO Nasdaq
- Market Cap
- ROIV 8.4B
- HALO 7.4B
- IPO Year
- ROIV N/A
- HALO N/A
- Fundamental
- Price
- ROIV $10.79
- HALO $52.02
- Analyst Decision
- ROIV Buy
- HALO Buy
- Analyst Count
- ROIV 4
- HALO 9
- Target Price
- ROIV $17.50
- HALO $63.56
- AVG Volume (30 Days)
- ROIV 5.9M
- HALO 3.1M
- Earning Date
- ROIV 05-29-2025
- HALO 05-06-2025
- Dividend Yield
- ROIV N/A
- HALO N/A
- EPS Growth
- ROIV N/A
- HALO 55.40
- EPS
- ROIV N/A
- HALO 3.76
- Revenue
- ROIV $122,585,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- ROIV N/A
- HALO $24.79
- Revenue Next Year
- ROIV N/A
- HALO $22.65
- P/E Ratio
- ROIV N/A
- HALO $13.83
- Revenue Growth
- ROIV 140.04
- HALO 25.64
- 52 Week Low
- ROIV $8.73
- HALO $41.28
- 52 Week High
- ROIV $13.06
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- ROIV 50.06
- HALO 39.78
- Support Level
- ROIV $10.58
- HALO $47.50
- Resistance Level
- ROIV $11.77
- HALO $69.94
- Average True Range (ATR)
- ROIV 0.34
- HALO 3.52
- MACD
- ROIV -0.07
- HALO -1.49
- Stochastic Oscillator
- ROIV 17.65
- HALO 19.64
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.